Am. J. Respir. Cell Mol. Biol., Volume 20, Number 1, January, 1999 129-134

The In Vivo Effects of Milrinone on the Airways of Cystic Fibrosis Mice and Human Subjects

Stephen N. Smith, Peter G. Middleton, Sharon Chadwick, Adam Jaffe, Katy A. Bush, Sarah Rolleston, Ray Farley, Stephen J. Delaney, Brandon Wainwright, Duncan M. Geddes, and Eric W. F. W. Alton

Ion Transport Unit, National Heart and Lung Institute at Imperial College, London, United Kingdom; Department of Respiratory Medicine, Westmead Hospital, Sydney, Australia; and Department for Molecular and Cellular Biology, University of Queensland, Brisbane, Australia

Previous studies have indicated that milrinone, a specific type III phosphodiesterase inhibitor, may be able to induce chloride secretion in cystic fibrosis (CF) tissues. We have now assessed the effect of this agent in vivo on the nasal epithelium of CF mutant mice and also in the nose and lungs of human subjects with CF. Wild-type mice showed a small hyperpolarization of the nasal potential difference (PD) in response to milrinone (100 µM, 1.6 ± 0.6 mV, n = 8, P < 0.05). In contrast, CF mice carrying either the most common human mutation of the gene for the CF transmembrane regulator (CFTR), F508 (protein mislocalized), or the G551D mutation (protein normally localized) failed to demonstrate this response. Milrinone perfused alone had no significant effect on the baseline nasal PD of human subjects without CF (14.7 ± 4.0 mV preperfusion; 15.3 ± 4.6 mV postperfusion), but significantly (P < 0.05) augmented the hyperpolarization induced by a subsequently perfused low-chloride solution (with milrinone, 36.8 ± 3.0 mV, n = 6; without milrinone, 18.1 ± 2.2 mV, n = 19). In contrast, in human subjects with CF (n = 6), milrinone alone significantly (P < 0.05) altered the nasal baseline PD (52.2 ± 3.3 mV preperfusion; 57.4 ± 4.2 mV, postperfusion) but not the subsequent responses to the low-chloride solution (with milrinone, 1.1 ± 2.2 mV, n = 4; without milrinone, 0.6 ± 0.5 mV, n = 28) or to isoproterenol (100 µM). In a separate study in subjects (n = 6) with the F508 mutation, nasal coadministration of milrinone with isoproterenol produced no effect in the presence of amiloride and a low-chloride solution (0.8 ± 0.5 mV). This was also the case in the nasal epithelium of CF subjects (n = 4) carrying at least one G551D allele (0.3 ± 0.8 mV). Similarly, milrinone did not hyperpolarize the PD of either the tracheal (n = 6) or segmental (n = 6) airways of CF subjects (F508) when applied topically in vivo in the presence of amiloride, isoproterenol, or adenosine triphosphate (all 100 µM) in a low-chloride solution. These data do not support the use of milrinone to induce chloride secretion in CF airways in vivo.

This article has been cited by other articles:

				L. L. Clarke Phosphodiesterase 5 Inhibitors and Cystic Fibrosis: Correcting Chloride Channel Dysfunction Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 469 - 470. [Full Text] [PDF]

				B. Lubamba, H. Lecourt, J. Lebacq, P. Lebecque, H. De Jonge, P. Wallemacq, and T. Leal Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 506 - 515. [Abstract] [Full Text] [PDF]

				S. M. Rowe, F. Accurso, and J. P. Clancy Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials Proceedings of the ATS, August 1, 2007; 4(4): 387 - 398. [Abstract] [Full Text] [PDF]

				B. R. Grubb, T. D. Rogers, H. M. Kulaga, K. A. Burns, R. L. Wonsetler, R. R. Reed, and L. E. Ostrowski Olfactory epithelia exhibit progressive functional and morphological defects in CF mice Am J Physiol Cell Physiol, August 1, 2007; 293(2): C574 - C583. [Abstract] [Full Text] [PDF]

				A. P. Barnes, G. Livera, P. Huang, C. Sun, W. K. O'Neal, M. Conti, M. J. Stutts, and S. L. Milgram Phosphodiesterase 4D Forms a cAMP Diffusion Barrier at the Apical Membrane of the Airway Epithelium J. Biol. Chem., March 4, 2005; 280(9): 7997 - 8003. [Abstract] [Full Text] [PDF]

				E. W. F. W. Alton and on behalf of the United Kingdom Cystic Fibrosis Ge Use of Nonviral Vectors for Cystic Fibrosis Gene Therapy Proceedings of the ATS, December 1, 2004; 1(4): 296 - 301. [Abstract] [Full Text] [PDF]

				B. R. Cobb, L. Fan, T. E. Kovacs, E. J. Sorscher, and J. P. Clancy Adenosine Receptors and Phosphodiesterase Inhibitors Stimulate Cl- Secretion in Calu-3 Cells Am. J. Respir. Cell Mol. Biol., September 1, 2003; 29(3): 410 - 418. [Abstract] [Full Text] [PDF]

				J. B. Lyczak, C. L. Cannon, and G. B. Pier Lung Infections Associated with Cystic Fibrosis Clin. Microbiol. Rev., April 1, 2002; 15(2): 194 - 222. [Abstract] [Full Text] [PDF]

				P. Dickinson, S. N. Smith, S. Webb, F. M. Kilanowski, I. J. Campbell, M. S. Taylor, D. J. Porteous, R. Willemsen, H. R. de Jonge, R. Farley, et al. The severe G480C cystic fibrosis mutation, when replicated in the mouse, demonstrates mistrafficking, normal survival and organ-specific bioelectrics Hum. Mol. Genet., February 1, 2002; 11(3): 243 - 251. [Abstract] [Full Text] [PDF]

				J. J. Haddad, S. C. Land, W. O. Tarnow-Mordi, M. Zembala, D. Kowalczyk, and R. Lauterbach Immunopharmacological Potential of Selective Phosphodiesterase Inhibition. I. Differential Regulation of Lipopolysaccharide-Mediated Proinflammatory Cytokine (Interleukin-6 and Tumor Necrosis Factor-alpha ) Biosynthesis in Alveolar Epithelial Cells J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 559 - 566. [Abstract] [Full Text] [PDF]

				B. R. Cobb, F. Ruiz, C. M. King, J. Fortenberry, H. Greer, T. Kovacs, E. J. Sorscher, and J. P. Clancy A2 adenosine receptors regulate CFTR through PKA and PLA2 Am J Physiol Lung Cell Mol Physiol, January 1, 2002; 282(1): L12 - L25. [Abstract] [Full Text] [PDF]

				K. G. Brady, T. J. Kelley, and M. L. Drumm Examining basal chloride transport using the nasal potential difference response in a murine model Am J Physiol Lung Cell Mol Physiol, November 1, 2001; 281(5): L1173 - L1179. [Abstract] [Full Text] [PDF]

				J. P. CLANCY, Z. BEBOK, F. RUIZ, C. KING, J. JONES, L. WALKER, H. GREER, J. HONG, L. WING, M. MACALUSO, et al. Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1683 - 1692. [Abstract] [Full Text] [PDF]

				P.G. Middleton, K.A. Pollard, and J.R. Wheatley Hypertonic saline alters ion transport across the human airway epithelium Eur. Respir. J., February 1, 2001; 17(2): 195 - 199. [Abstract] [Full Text] [PDF]